1.国家自然科学基金项目

(1)癌代谢物D-2-HG介导骨骼肌-免疫相互作用促进恶病质肌萎缩作用机制研究, 62.0万元，2023.1-2026.12，主持，在研

(2)BCKDK介导支链氨基酸代谢异常在恶病质骨骼肌蛋白合成的作用及机制，57.0万元，2019.1-2022.12，主持，结题

(3)β2-AR激动剂福莫特罗调控BCKDC改善恶病质骨骼肌萎缩的作用机制研究，17.9万元，2016.1-2018.12，主持，结题

(4)苦参碱通过BDK/BCKDC通路改善肿瘤恶病质骨骼肌萎缩的作用及机制， 57.0万元，2018.1-2022.12，参与，结题

(5)胆淤方通过PDC-E2调控丙酮酸代谢改善PBC胆管上皮细胞损伤的作用和机制，17.9万元，2019.1-2022.12，参与，结题

(6)心肌成纤维细胞和TGF-β1/Smads信号通路在阿霉素心脏毒性中的作用及机制研究，17.9万元，2019.1-2022.12，参与，结题

(7)消癌平注射液通过调控PXR/CAR增强紫杉醇抗卵巢癌的作用机制研究，55.0万元，2018.1-2021.12，参与，结题

(8)基于CerK调控脊髓星形胶质细胞活化对骨癌痛的作用及机制研究，17.3万元，2018.1-2021.12，参与，结题

(9)基于核糖体蛋白S5的木犀草素抗肝纤维化新靶点及机制研究，17.9万元，2016.1-2018.12，参与，结题

(10)多奈哌齐立体选择性代谢和转运机制及相关候选基因研究，23万元，2013.1-2016.12，参与，结题。

2.人才项目

（1）上海市浦江人才(A类)，2021.11，项目编号： 21PJ141900

（2）上海市卫生计生系统优秀青年医学人才，2018.7，项目编号：2018YQ19

（3）上海交通大学医学院研究型医师项目（双百人项目），2024.8， 项目编号：20240815

（4）中国药学会医院药学专委会拔尖人才项目，2022.10

（5）上海市药学会青年药学人才能力提升项目，2023.2 

3.发表论文

[1] L. Mao, J. Lu, Q. Yang, Z. Liu, C. Wu, B. Ke, K. Su, H. Yuan, Y. Cui, Y. Wang, R. Salvi, G. Yang, S. Yin, F. Liu, and C. Li, Bilirubin Targeting WNK1 to Alleviate NLRP3-Mediated Neuroinflammation. Adv Sci (Weinh) 12 (2025) e2407349.

[2] M. Xiao, C. Guo, and Q. Yang, MR analysis reveals no causal association between mitochondrial DNA copy number and osteoporosis. Sci Rep 15 (2025) 22286.

[3] L. Han, K. Chen, J. Liu, H. Yan, Y. Fang, D. Bai, Y. Zhou, L. Jing, C. Guo, Y. Zhu, and Q. Yang, Agrimonolide from Agrimonia pilosa Ledeb attenuates cholestatic liver injury and macrophage infiltration via the inhibition of bile acid excretion transporters. Int Immunopharmacol (2025) 115186.

[4] X. Zhu, L. Han, D. Bai, L. Yi, Y. Zhao, S. Liu, R. Gan, B. Xin, Y. Tu, J. Zhang, Y. Han, J. Hao, Z. Xuan, C. Guo, and Q. Yang, Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL. Mol Ther (2025).

[5] D. Bai, Y. Zhou, L. Jing, C. Guo, and Q. Yang, Arginine Metabolism in Cancer Biology and Immunotherapy. Immune Netw 25 (2025) e30.

[6] S. Liu, J. Miao, H. Li, G. Ge, Q. Yang, S. Zhao, and C. Guo, The regulatory roles of pparα on hepatic drug-metabolizing enzymes in primary sclerosing cholangitis Syrian hamsters. Biochem Pharmacol 242 (2025) 117339.

[7] J. Hao, J. Wu, Q. Yang, K. Lu, Y. Xu, Y. Chen, J. Liu, X. Shao, C. Zhu, Y. Ding, and X. Xie, Gentiopicroside Ameliorated Ductular Reaction and Inflammatory Response in DDC-induced Murine Cholangiopathies Model. Curr Mol Pharmacol 17 (2024) e18761429251911.

[8] S. Qu, X. Zhou, Z. Wang, Y. Wei, H. Zhou, X. Zhang, Q. Zhu, Y. Wang, Q. Yang, L. Jiang, Y. Ma, Y. Gao, L. Kong, and L. Zhang, The effects of methylphenidate and atomoxetine on Drosophila brain at single-cell resolution and potential drug repurposing for ADHD treatment. Mol Psychiatry 29 (2024) 165-185.

[9] C. Li, Q. Yang, and L. Zhang, Identification of putative allosteric inhibitors of BCKDK via virtual screening and biological evaluation. J Enzyme Inhib Med Chem 39 (2024) 2290458.

[10] L. Chen, H. Zhang, M. Chi, Y. Wang, X. Zhu, L. Han, B. Xin, R. Gan, Y. Tu, X. Sun, J. Lu, J. Li, J. Huang, J. Zhang, Y. Han, C. Guo, and Q. Yang, Bckdk-Mediated Branch Chain Amino Acid Metabolism Reprogramming Contributes to Muscle Atrophy during Cancer Cachexia. Mol Nutr Food Res 68 (2024) e2300577.

[11] L. Wei, J. Meng, D. Xiang, Q. Yang, Y. Zhou, L. Xu, M. Wang, J. Chen, and Y. Han, Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma. BMC Complement Med Ther 24 (2024) 67.

[12] J. Lu, J. Zhang, X. Wang, F. Yuan, B. Xin, J. Li, Q. Yang, X. Li, J. Zhang, X. Wang, J. Fu, and C. Guo, Dl-3-n-butylphthalide promotes microglial phagocytosis and inhibits microglial inflammation via regulating AGE-RAGE pathway in APP/PS1 mice. Brain Res Bull 212 (2024) 110969.

[13] Q. Yang, X. Zhu, P. Huang, C. Li, L. Han, Y. Han, R. Gan, B. Xin, Y. Tu, S. Zhou, T. Yuan, J. Hao, C. Li, L. Zhang, L. Shi, and C. Guo, BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism. Mol Ther 32 (2024) 3128-3144.

[14] M. Tuerxun, X. Zheng, J. Xu, Q. Yang, T. Yuan, C. Zhang, and S. Zhou, High expression of DEC2 distinguishes chondroblastic osteosarcoma and promotes tumour growth by activating the VEGFC/VEGFR2 signalling pathway. J Cell Mol Med 28 (2024) e18462.

[15] L. Wei, J. Meng, D. Xiang, Q. Yang, Y. Zhou, L. Xu, J. Chen, and Y. Han, The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 as an Immune Marker in Tumor. Int J Gen Med 17 (2024) 2593-2612.

[16] C. Wu, S. Liu, L. Zhou, Z. Chen, Q. Yang, Y. Cui, M. Chen, L. Li, B. Ke, C. Li, and S. Yin, Cellular and Molecular Insights into the Divergence of Neural Stem Cells on Matrigel and Poly-l-lysine Interfaces. ACS Appl Mater Interfaces 16 (2024) 31922-31935.

[17] M.M. Zhang, M.J. Liang, D.M. Zhang, J.N. Cai, Q.J. Yang, Y. Zhao, J.P. Zhang, and Y.L. Li, The function and mechanism of LAPTM5 in diseases. Biomed Pharmacother 178 (2024) 117237.

[18] J. Chen, Q. Yang, X. Xu, X. Wu, Y. Han, C. Guo, and J. Yang, Outcome differences of starting Paxlovid for COVID-19 within or after five days of symptoms onset in the elderly: a retrospective study. J Infect Dev Ctries 18 (2024) 1373-1379.

[19] X. Sun, L. Zhou, Y. Han, Q. Yang, X. Li, B. Xin, M. Chi, Y. Wang, and C. Guo, Scutellarin Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Myocardial Fibrosis, Apoptosis and Autophagy in Rats. Chem Biodivers 20 (2023) e202200450.

[20] X. Zhao, R. Xu, Y. Wang, Y. Zhou, J. Lu, W. Zhu, Y. Qiu, Q. Yang, Z. Shen, C. Guo, and J. Zhang, Adherence to Analgesic Drugs and its Associated Factors among Patients with Cancer Pain: A Crosssectional Study in China. Am J Health Beh** 47 (2023) 30-39.

[21] Y. Wang, X. Sun, Q. Yang, and C. Guo, Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway. Phytother Res 37 (2023) 3380-3393.

[22] Y.D. Zhu, X.Y. Ma, L.P. Li, Q.J. Yang, F. Jin, Z.N. Chen, C.P. Wu, H.B. Shi, Z.Q. Feng, S.K. Yin, and C.Y. Li, Surface Functional Modification by Ti(3) C(2) T(x) MXene on PLLA Nanofibers for Optimizing Neural Stem Cell Engineering. Adv Healthc Mater 12 (2023) e2300731.

[23] J. Hao, X. Shen, K. Lu, Y. Xu, Y. Chen, J. Liu, X. Shao, C. Zhu, Y. Ding, X. Xie, J. Wu, and Q. Yang, Costunolide alleviated DDC induced ductular reaction and inflammatory response in murine model of cholestatic liver disease. J Tradit Complement Med 13 (2023) 345-357.

[24] X. Zhu, J. Hao, H. Zhang, M. Chi, Y. Wang, J. Huang, R. Xu, Z. Xincai, B. Xin, X. Sun, J. Zhang, S. Zhou, D. Cheng, T. Yuan, J. Ding, S. Zheng, C. Guo, and Q. Yang, Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia. Commun Biol 6 (2023) 977.

[25] Z. Xuan, J. Song, Q. Yang, and P. Huang, Editorial: Studying novel immune signatures, targets, and drugs in hepatobiliary tumors: based on advanced technologies. Front Immunol 14 (2023) 1322220.

[26] L. Wei, X. Xue, J. Chen, Q. Yang, M. Wang, and Y. Han, Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma. Journal of Shanghai Jiaotong University. Medical Science 43 (2023) 624-630.

[27] J. Hao, X. Shen, X. Shao, C. Zhu, K. Lu, Y. Xu, Y. Chen, J. Liu, Y. Ding, X. Xie, J. Wu, and Q. Yang, Honokiol attenuates ductular reaction, regulates of bile acids metabolism, and inhibits inflammatory response in murine cholestatic liver injury model. ARABIAN JOURNAL OF CHEMISTRY 16 (2023).

[28] Zhou Y, Li C, Bai D, Jing L, Han L, Guo C, Yang Q. Proline metabolism reprogramming in cancer reveals the regulation of PRODH/POX as target. Biomed Pharmacother. 2026;195:119040.

[29] P. Renauer, J.J. Park, M. Bai, A. Acosta, W.-H. Lee, G.H. Lin, Y. Zhang, X. Dai, G. Wang, Y. Errami, T. Wu, P. Clark, L. Ye, Q. Yang, and S. Chen, Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function. Cancer Immunol Res. 2023 Aug 3;11(8):1068-1084.

[30] Q. Yang, J. Hao, M. Chi, Y. Wang, J. Li, J. Huang, J. Zhang, M. Zhang, J. Lu, S. Zhou, T. Yuan, Z. Shen, S. Zheng, and C. Guo, D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. Mol Ther 30 (2022) 1188-1200.

[31] M.Y. Chi, H. Zhang, Y.X. Wang, X.P. Sun, Q.J. Yang, and C. Guo, Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK/FoxO and JNK/FoxO Pathways. Oxid Med Cell Longev 2022 (2022) 5694223.

[32] C. Zhou, Y. Sun, Z. Gong, J. Li, X. Zhao, Q. Yang, H. Yu, J. Ye, J. Liang, L. Jiang, D. Zhang, Z. Shen, and S. Zheng, FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment. J Bone Miner Res 37 (2022) 885-895.

[33] Q. Yang, J. Hao, M. Chi, Y. Wang, B. Xin, J. Huang, J. Lu, J. Li, X. Sun, C. Li, Y. Huo, J. Zhang, Y. Han, and C. Guo, Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology 11 (2022) 2055703.

[34] S. Lin, Y. Miao, X. Zheng, Y. Dong, Q. Yang, Q. Yang, S. Du, J. Xu, S. Zhou, and T. Yuan, ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism. Cell Death Discov 8 (2022) 225.

[35] L. Zhou, Y. Han, Q. Yang, B. Xin, M. Chi, Y. Huo, C. Guo, and X. Sun, Scutellarin attenuates doxorubicin-induced oxidative stress, DNA damage, mitochondrial dysfunction, apoptosis and autophagy in H9c2 cells, cardiac fibroblasts and HUVECs. Toxicol In Vitro 82 (2022) 105366.

[36] S. Qu, Q. Zhu, H. Zhou, Y. Gao, Y. Wei, Y. Ma, Z. Wang, X. Sun, L. Zhang, Q. Yang, L. Kong, and L. Zhang, EasyFlyTracker: A Simple Video Tracking Python Package for Analyzing Adult Drosophila Locomotor and Sleep Activity to Facilitate Revealing the Effect of Psychiatric Drugs. FRONTIERS IN BEHAVIORAL NEUROSCIENCE 15 (2022).

[37] L.P. Ye, J.J. Park, L. Peng, Q.J. Yang, R.D. Chow, M.B. Dong, S.Z. Lam, J.J. Guo, E.T. Tang, Y.Q. Zhang, G.C. Wang, X.Y. Dai, Y.Y. Du, H.R. Kim, H.B. Cao, Y. Errami, P. Clark, A. Bersenev, R.R. Montgomery, S.D. Chen, R.R. Montgomery, and S.D. Chen, A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab 34 (2022) 595-+.

[38] H. Zhang, M. Chi, L. Chen, X. Sun, L. Wan, Q. Yang, and C. Guo, Daidzein alleviates cisplatin-induced muscle atrophy by regulating Glut4/AM**/FoxO pathway. Phytother Res 35 (2021) 4363-4376.

[39] S. Zheng, F. Wang, J. Huang, Y. Zhou, Q. Yang, G. Qian, C. Zhou, D. Min, L. Song, and Z. Shen, Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden. Front Endocrinol (Lausanne) 12 (2021) 625226.

[40] S. Lin, L. Zhou, Y. Dong, Q. Yang, Q. Yang, H. Jin, T. Yuan, and S. Zhou, Alpha-(1,6)-fucosyltransferase (FUT8) affects the survival strategy of osteosarcoma by remodeling TNF/NF-κB2 signaling. Cell Death Dis 12 (2021) 1124.

[41] S. Qu, Q. Zhu, H. Zhou, Y. Gao, Y. Wei, Y. Ma, Z. Wang, X. Sun, L. Zhang, Q. Yang, L. Kong, and L. Zhang, EasyFlyTracker: A Simple Video Tracking Python Package for Analyzing Adult Drosophila Locomotor and Sleep Activity to Facilitate Revealing the Effect of Psychiatric Drugs. Front Beh** Neurosci 15 (2021) 809665.

[42] H. Zhang, M. Chi, Y. Wang, L. Chen, X. Sun, L. Wan, Q. Yang, and C. Guo, Naringenin alleviates cisplatin induced muscle atrophy by regulating RI**1/AM**/NF-κB pathway. JOURNAL OF FUNCTIONAL FOODS 86 (2021).

[43] Liu B, Wang G, Yang Q, Yu Y, Su Y, Huang W, Wang P, Yan D, Huang P.A charge-reversal prodrug activated by tumor-acidity for selective cancer chemotherapy. Biomater Sci. 2026;14(4):1052-1061. 

[44] W. Qu, Q. Yang, G. Wang, Z. Wang, P. Huang, W. Huang, R. Zhang, and D. Yan, Amphiphilic irinotecan-melampomagnolide B conjugate nanoparticles for cancer chemotherapy. RSC Adv 10 (2020) 8958-8966.

[45] L. Chen, W. Xu, Q. Yang, H. Zhang, L. Wan, B. Xin, J. Zhang, and C. Guo, Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol Res 158 (2020) 104871.

[46] H. Zhang, L. Chen, X. Sun, Q. Yang, L. Wan, and C. Guo, Matrine: A Promising Natural Product With Various Pharmacological Activities. Front Pharmacol 11 (2020) 588.

[47] L. Chen, Q. Yang, H. Zhang, L. Wan, B. Xin, Y. Cao, J. Zhang, and C. Guo, Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway. J Ethnopharmacol 260 (2020) 113066.

[48] H. Zhang, M. Chi, L. Chen, X. Sun, L. Wan, Q. Yang, and C. Guo, Linalool Prevents Cisplatin Induced Muscle Atrophy by Regulating IGF-1/Akt/FoxO Pathway. Front Pharmacol 11 (2020) 598166.

[49] W. Qu, Q. Yang, P. Huang, W. Huang, and D. Yan, Preparation and Property of PEGylated Melampomagnolide B Prodrug Nanoparticles for Cancer Therapy. Journal of Functional Polymer 33 (2020) 275-283.

[50] Q. Yang, J. Zhang, J. Yu, R. Xu, Y. Zhao, P. Zhang, and C. Guo, Construction of Structured Pharmaceutical Knowledge Database for the Improvement of Drug Decision Support System. Chinese Journal of Modern Applied Pharmacy 37 (2020) 490-495.

[51] L. Chen, L. Chen, L. Wan, Y. Huo, J. Huang, J. Li, J. Lu, B. Xin, Q. Yang, and C. Guo, Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice. Oncol Rep 42 (2019) 479-494.

[52] L.P. Ye, J.J. Park, M.B. Dong, Q.J. Yang, R.D. Chow, L. Peng, Y.Y. Du, J.J. Guo, X.Y. Dai, G.C. Wang, Y. Errami, and S.D. Chen, In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat Biotechnol 37 (2019) 1302.

[53] Q.J. Yang, J.R. Zhao, J. Hao, B. Li, Y. Huo, Y.L. Han, L.L. Wan, J. Li, J. Huang, J. Lu, G.J. Yang, and C. Guo, Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. J Cachexia Sarcopenia Muscle 9 (2018) 71-85.

[54] J. Lu, J. Fu, Y. Zhong, Q. Yang, J. Huang, J. Li, Y. Huo, Y. Zhao, L. Wan, and C. Guo, Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer's disease. Brain Res Bull 140 (2018) 1-4.

[55] L. Wan, J. Lu, J. Fu, J. Huang, Q. Yang, B. Xin, L. Chen, Y. Huo, Y. Zhong, and C. Guo, Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer's Disease. Curr Alzheimer Res 15 (2018) 917-927.

[56] J. Huang, L. Wan, Y. Huo, J. Li, Q. Yang, J. Lu, R. Gan, and C. Guo, Visualized analysis of research status on global drug-induced liver injury based on GoPubMed. Adverse Drug Reactions Journal 20 (2018) 38-42.

[57] Y. Quan-Jun, H. Yan, H. Yong-Long, W. Li-Li, L. Jie, H. Jin-Lu, L. Jin, C. Peng-Guo, G. Run, and G. Cheng, Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation. Mol Cancer Ther 16 (2017) 334-343.

[58] Y. Quan-Jun, Z. Jian-Ping, Z. Jian-Hua, H. Yong-Long, X. Bo, Z. Jing-Xian, D. Bona, Z. Yuan, and G. Cheng, Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation. Basic Clin Pharmacol Toxicol 120 (2017) 303-311.

[59] Y. QuanJun, Y. GenJin, W. LiLi, H. YongLong, H. Yan, L. Jie, H. JinLu, L. Jin, G. Run, and G. Cheng, Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study. PLoS One 12 (2017) e0169567.

[60] X.P. Sun, L.L. Wan, Q.J. Yang, Y. Huo, Y.L. Han, and C. Guo, Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. Arch Pharm Res 40 (2017) 875-883.

[61] J. Lu, J. Fu, Y. Zhong, P. Chen, Q. Yang, Y. Zhao, L. Wan, and C. Guo, The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease. Neurosci Lett 614 (2016) 43-8.

[62] J.L. Huang, Y. Huo, L.L. Wan, Q.J. Yang, J. Li, and C. Guo, CERK might contribute to inflammatory pain; Comments on Yu WL, Sun. Y (2015). CERK inhibition might be a good potential therapeutic target for diseases. Br J Pharmacol 172: 2165. Br J Pharmacol 173 (2016) 1248-9.

[63] Z.Y. Zhou, L.L. Wan, Q.J. Yang, Y.L. Han, D. Li, J. Lu, and C. Guo, Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model. Toxicol Lett 259 (2016) 124-132.

[64] P. Chen, J. Li, Y. Huo, J. Lu, L. Wan, Q. Yang, J. Huang, R. Gan, and C. Guo, Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats. Sci Rep 6 (2016) 33593.

[65] L.Y. Liu, Y.L. Han, J.H. Zhu, Q. Yu, Q.J. Yang, J. Lu, and C. Guo, A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates. Biomed Chromatogr 29 (2015) 437-44.

[66] B. Li, R. Gan, Q. Yang, J. Huang, P. Chen, L. Wan, and C. Guo, Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2015 (2015) 350730.

[67] Q. Yang, G. Yang, L. Wan, Y. Huo, Y. Han, J. Lu, J. Li, J. Huang, and C. Guo, Integrated analysis of serum and intact muscle metabonomics identify metabolic profiles of cancer cachexia in a dynamic mouse model. RSC ADVANCES 5 (2015) 92438-92448.

[68] B. Li, R. Gan, Q. Yang, J. Huang, P. Chen, L. Wan, Q. Yu, and C. Guo, Influence of formulas based on different principles of traditional Chinese medicine on cachexia muscle atrophy of mice induced by CT26 adenocarcinoma. China Journal of Traditional Chinese Medicine and Pharmacy 30 (2015) 1696-1700.

[69] Y.L. Han, D. Li, Q.J. Yang, Z.Y. Zhou, L.Y. Liu, B. Li, J. Lu, and C. Guo, In vitro inhibitory effects of scutellarin on six human/rat cytochrome P450 enzymes and P-glycoprotein. Molecules 19 (2014) 5748-60.

[70] B. Li, L. Wan, Y. Li, Q. Yu, P. Chen, R. Gan, Q. Yang, Y. Han, and C. Guo, Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia. Tumour Biol 35 (2014) 12415-25.

[71] J. Li, X. Li, Y. Huo, Q. Yang, and C. Guo, Effects of Luteloin on the Migration and Proliferation of Hepatic Stellate Cells. China Pharmacy 25 (2014) 580-582.

[72] B. Li, L. Wan, Y. Li, Q. Yang, Q. Yu, and C. Guo, Effect of Sijunzi Decoction on Cancer Cachexia in Colon Adenocarcinoma-Bearing Mice. Journal of Traditional Chinese Medicine 55 (2014) 1584-1587.

[73] Q. Yang, J. Zhang, L. Guo, R. Xu, J. Yu, and C. Guo, Analysis of the Utilization of Enteral and Parenteral Nutrition Preparation in 34 Hospitals of Shanghai during 2011-2013. China Pharmacy 25 (2014) 3948-3951.

[74] Y.-L. Han, D. Li, Q.-J. Yang, Z.-Y. Zhou, L.-Y. Liu, B. Li, J. Lu, and C. Guo, In Vitro Inhibitory Effects of Scutellarin on Six Human/Rat Cytochrome P450 Enzymes and P-glycoprotein. MOLECULES 19 (2014) 5748-5760.

[75] Z. Zhou, L. Wan, Y. Han, X. Meng, Q. Yang, Y. Li, Q. Yu, Z. Shen, and C. Guo, ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. Pharm Biol 51 (2013) 968-73.

[76] Q. Yang, L. Wan, Z. Zhou, Y. Li, Q. Yu, L. Liu, B. Li, and C. Guo, Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma. Phytomedicine 20 (2013) 992-8.

[77] Z.Y. Zhou, L.L. Wan, Q.J. Yang, Y.L. Han, Y. Li, Q. Yu, C. Guo, and X. Li, Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib. Toxicol Appl Pharmacol 272 (2013) 238-44.

[78] Y. Quanjun, Y. Genjin, W. Lili, L. Bin, L. Jin, Y. Qi, L. Yan, H. Yonglong, G. Cheng, and Z. Junping, Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice. Mol Biosyst 9 (2013) 3015-25.

[79] Q. Yang, B. Wu, Y. Shi, X. Du, M. Fan, Z. Sun, X. Cui, and C. Huang, Bioactivity-guided fractionation and analysis of compounds with anti-influenza virus activity from Gardenia jasminoides Ellis. Arch Pharm Res 35 (2012) 9-17.

[80] Y. Lin, Z. Li, B. Wu, Q. Yang, J. Jiang, and C. Huang, QUALITY ASSESSMENT FOR PORTULACA OLERACEA BY MULTI-COMPONENT QUANTIFICATION, CHROMATOGRAPHIC FINGERPRINT AND RELATED CHEMOMETRIC ANALYSIS. JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 35 (2012) 2655-2668.

4.荣誉获奖

(1)2020.12 新冠肺炎疫情防控的应急药学服务体系建设，上海市科学技术奖，三等奖，上海市人民政府 

(2)2021.7 肿瘤营养诊疗关键技术研究与推广，北京医学科技奖，一等奖，北京医学会

(3)2023.5 2022年度医院药学特殊贡献奖， 上海市合理用药宣传月系列活动领导小组

(4)2025.3 2024年度上海市医院协会临床药师管理专委会 先进个人

(5)2021.11 2021年度上海市医学会临床药学专科分会学术年会，药学菁英，上海市医学会临床药学专科分会

(6)2020.9 中成药致急慢性肝损伤的原因析要及防范，上海交通大学医学院药学管理专委会第七届医院药学学术年会，优秀奖，上海交通大学医学院医院管理处

(7)2017.9 从代谢角度分析右丙亚胺对阿霉素心脏毒性的保护的潜在生物标志物，2017年医院药学青年论文报告会，一等奖，上海市药学会

(8)2016.9 司美替尼通过抑制ERK改善肿瘤恶病质骨骼肌萎缩的实验研究，2016上海医院药学学术年会，一等奖，上海市药学会

(9)2015.11 基于NMR的代谢组学揭示姜黄素调控肿瘤恶病质代谢重编程，2015年上海市医院药学青年论文报告会，一等奖，上海市药学会

(10)2014.11 上海市34家医院2011-2013年肠内肠外营养制剂应用分析，第十三届全国青年药学成才之路论坛，优秀论文，中国药学会医院药学专委会